Eupraxia Pharmaceuticals Valuation
| EPRXF Stock | USD 2.67 0.05 1.91% |
Based on Macroaxis valuation methodology, the firm appears to be overvalued. Eupraxia Pharmaceuticals shows a prevailing Real Value of $2.56 per share. The current price of the firm is $2.67. Our model computes the value of Eupraxia Pharmaceuticals from reviewing the firm fundamentals such as Current Valuation of 43.78 M, price to book of 3.89 X, and Shares Owned By Insiders of 12.40 % as well as analyzing its technical indicators and probability of bankruptcy. In general, most investors advise locking in undervalued instruments and disposing overvalued instruments since, at some point, asset prices and their ongoing real values will submerge.
Overvalued
Today
Please note that Eupraxia Pharmaceuticals' price fluctuation is dangerous at this time. Calculation of the real value of Eupraxia Pharmaceuticals is based on 3 months time horizon. Increasing Eupraxia Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Eupraxia Pharmaceuticals is useful when determining the fair value of the Eupraxia pink sheet, which is usually determined by what a typical buyer is willing to pay for full or partial control of Eupraxia Pharmaceuticals. Since Eupraxia Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Eupraxia Pink Sheet. However, Eupraxia Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.67 | Real 2.56 | Hype 2.67 |
The real value of Eupraxia Pink Sheet, also known as its intrinsic value, is the underlying worth of Eupraxia Pharmaceuticals Company, which is reflected in its stock price. It is based on Eupraxia Pharmaceuticals' financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of Eupraxia Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Eupraxia Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Eupraxia Pharmaceuticals helps investors to forecast how Eupraxia pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Eupraxia Pharmaceuticals more accurately as focusing exclusively on Eupraxia Pharmaceuticals' fundamentals will not take into account other important factors: Eupraxia Pharmaceuticals Valuation Ratios as Compared to Competition
Comparative valuation techniques use various fundamental indicators to help in determining Eupraxia Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Eupraxia Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Eupraxia Pharmaceuticals competition to find correlations between indicators driving Eupraxia Pharmaceuticals's intrinsic value. More Info.Eupraxia Pharmaceuticals is one of the top stocks in price to book category among related companies. It is one of the top stocks in net asset category among related companies making up about 8,024,588 of Net Asset per Price To Book. Comparative valuation analysis is a catch-all model that can be used if you cannot value Eupraxia Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Eupraxia Pharmaceuticals' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Eupraxia Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Eupraxia Pharmaceuticals' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Eupraxia Pharmaceuticals and how it compares across the competition.
About Eupraxia Pharmaceuticals Valuation
The pink sheet valuation mechanism determines the current worth of Eupraxia Pharmaceuticals on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Eupraxia Pharmaceuticals. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Eupraxia Pharmaceuticals based exclusively on its fundamental and basic technical indicators. By analyzing Eupraxia Pharmaceuticals's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Eupraxia Pharmaceuticals's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Eupraxia Pharmaceuticals. We calculate exposure to Eupraxia Pharmaceuticals's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Eupraxia Pharmaceuticals's related companies.Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012.Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada. Eupraxia Pharmaceuticals operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 19 people.
8 Steps to conduct Eupraxia Pharmaceuticals' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Eupraxia Pharmaceuticals' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Eupraxia Pharmaceuticals' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Eupraxia Pharmaceuticals' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Eupraxia Pharmaceuticals' revenue streams: Identify Eupraxia Pharmaceuticals' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Eupraxia Pharmaceuticals' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Eupraxia Pharmaceuticals' growth potential: Evaluate Eupraxia Pharmaceuticals' management, business model, and growth potential.
- Determine Eupraxia Pharmaceuticals' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Eupraxia Pharmaceuticals' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Eupraxia Pharmaceuticals Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as Eupraxia Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 14.2 M | |
| Retained Earnings | -74.2 M |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eupraxia Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Complementary Tools for Eupraxia Pink Sheet analysis
When running Eupraxia Pharmaceuticals' price analysis, check to measure Eupraxia Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eupraxia Pharmaceuticals is operating at the current time. Most of Eupraxia Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eupraxia Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eupraxia Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eupraxia Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |